Ryan Agas
@ryanagasmd
Followers
103
Following
183
Statuses
103
Asst Prof @USTFMSofficial, DRO Vice Chair @USThospital, & RadOnc Residency Training Officer @CardinalSantos🇵🇭 | Former GI/Sarc fellow @PeterMacRadOnc🇦🇺
National Capital Region
Joined August 2015
@PeterMacRadOnc @ClinOncology @PeterMacCC @PeterMacRes Thank you! Missing PeterMac too! Will definitely drop by the campus when I visit 🇦🇺soon 😊
0
1
4
RT @KrishanJethwa: 🚨SCIENCE Ph3 RCT🚨 🔥Check this one out🔥 cT2-4N0-3, T1N2-3 Eso SCC 1️⃣neo Carbo + nabPaclitaxel + Sintilimab 2️⃣nCRT 41…
0
23
0
RT @KrishanJethwa: 🚨ESOPEC Pub has landed!🚨 See data review below! For now, "standard" will appropriately shift to peri-operative FLOT BU…
0
45
0
RT @adelapoite: External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Trea…
0
4
0
RT @5_utr: ❗️ RCT of proton RT vs TACE in HCC mPFS for PBT vs TACE was not reached vs. 12 months, p = .002; with a whopping HR 3.62 (1.62–…
0
10
0
RT @ldawsonmd: Proud to see RTOG1112 RCT published!. Thanks to so many who helped make this possible. #teamwork ‘Hope the next #SBRT #HCC…
0
30
0
RT @5_utr: 🚨 🚨 RCT of SBRT vs RFA for recurrent small HCC HR for local progression free survival a whopping 0.45 (0.95 CI 0.24-0.87) with…
0
31
0
RT @NiuSanford: RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, a…
0
70
0
RT @jryckman3: @5_utr Fantastic! Here is the HR for SBRT vs. TACE in our work. EBRT was associated with improved PFS over TACE (HR: 0.37,…
0
13
0
RT @NiuSanford: Another setting where SBRT underutilized IMO in HCC is bridge to transplant. I am convinced w modern tech, SBRT can safely…
0
25
0
RT @DKirschMDPhD: Just in time for #CTOS2024: Thrilled to share SU2C-SARC032 (NCT03092323), a randomized trial of pembrolizumab in Stage 3…
0
56
0
RT @TROGfightcancer: Congrats to Prof Trevor Leong and TOPGEAR trial investigators on publication of significant findings at #ESMO24 and in…
0
2
0
RT @JAMAOnc: In this study of patients receiving combined locoregional and immunotherapies (LRT-IO) for unresectable HCC, 46% had complete…
0
12
0
RT @Erman_Akkus: ☢️Neoadjuvant CRT vs. ChT for initially unresectable locally advanced "Colon" cancer @eClinicalMed ➡️45 patients ✅R0 res…
0
79
0
RT @PeterMacRadOnc: 17 years in the making!! Hearty congrats to Prof Trevor Leong for his outstanding leadership of #TOPGEAR #gastriccancer…
0
10
0
RT @PrajnanDasMD: ⚙️⚙️⚙️TOPGEAR presented today at #ESMO24: Preop chemoRT increased pCR but did not improve PFS or OS, compared to periop c…
0
31
0
RT @NiuSanford: PANDAS-PRODIGE 44 mFOLFIRINOX +/- chemoRT (50.4 Gy) in borderline resectable pancreas cancer. No dif in R0 resection (1…
0
44
0
RT @jryckman3: 🚨 New Insights into Patterns of Locoregional Recurrence in #PancreaticCancer after TNT & Their Impact on Neoadjuvant RT Volu…
0
33
0
RT @DKirschMDPhD: Hypofractionated Preoperative Radiation Should Not Yet Be Used as Standard of Care for Extremity and Truncal Soft Tissue…
0
16
0